Dr. Robert S. Brown, Jr., the Gladys and Roland Harriman Professor of Medicine and Clinical Chief of the Division of Gastroenterology and Hepatology, served as lead author and investigator on a recent study, EXPEDITION-8, that used a new drug combination for chronic HCV (hepatitis C) and compensated cirrhosis of the liver. Results of the breakthrough 8-week drug regimen (glecaprevir/pibrentasivr) were published in the Journal of Hepatology. Dr. Brown and colleagues provided a presentation on the paper’s promising findings at The Liver Meeting hosted by the American Association for the Study of Liver Diseases in Boston, Massachusetts (November 8-12, 2019).
The direct-acting antiviral drug regimen was administered to 343 patients enrolled in the study and results showed high virological cure rates. In an MD Edge feature article, Internal Medicine News, Dr. Brown described the EXPEDITION-8 study in detail and noted that “The availability of an 8-week, pangenotypic regimen for all treatment-naive HCV-infected patients, regardless of cirrhosis status, may simplify the HCV care pathway, furthering progress towards HCV elimination.”
Seventy-one million people are affected with chronic HCV infection worldwide.
Journal of Hepatology: Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1–6 and compensated cirrhosis: The EXPEDITION-8 trial
MD Edge: Glecaprevir/pibrentasvir highly effective in HCV genotype 3, among others
Healio: EXPEDITION-8: Mavyret nearly perfect in 8-week regimen